-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile,...
More »SEARCH RESULT
Total Matching Records found : 151
Drug price tug of war: people vs others -S Srinivasan
-The Hindu Business Line The media have got it wrong on price control reversal Recently, there has been a flutter in various media channels and newspapers as to how the Modi Government has reversed certain drug price control measures announced in July 2014. As a result, we are told, prices of these drugs would increase much more than pre-July levels. This was supposed to be a sequel to Modi's visit to the...
More »New drug era -Shamnad Basheer
-The Indian Express Prime Minister Narendra Modi's US visit is likely to throw up highly contentious intellectual property rights issues. Indeed, for the last several years, US drug majors and their European counterparts have lobbied hard to demonise the Indian patent regime. But the government must continue to defend the law and stand its ground. Particularly since our own industrial moguls have caved in and are less vocal about their opposition...
More »Free drug policy to be streamlined for integration with National Health Mission
-Press Information Bureau (Ministry of Health and Family Welfare) Dr Harsh Vardhan, Union Minister for Health and Family Welfare, has asked for thorough streamlining of systems in the distribution of free generic drugs to government health institutions at all levels throughout the country. The Free Drug Programme's formal launch would be preceded by working out all logistical details with respect to procurement and distribution in consultation with the state governments. The...
More »Conflict of interest in setting norms for pharmaceuticals in WHO -Rema Nagarajan
-The Times of India NEW DELHI: The World Health Organisation's (WHO) work of setting up norms and standards for production of medicines seems to be flawed by a fundamental conflict of interest. At the heart of its standard setting work is an entity the International Conference on Harmonization (ICH) in which majority of the WHO member countries have no voting rights and which is dominated by pharmaceutical industry groups. This glaring...
More »
